Search for Melanoma Markers in Plasma and Serum Samples

Fourteen blood samples from patients with melanomas and 11 blood samples from healthy subjects were analyzed by matrix-assisted laser desorption/ionization mass spectrometry. The study focussed on species of low molecular weight, in the 800–5000 Da range, present in plasma and sera. While for healthy subjects plasma samples lead to the production of a higher number of ionic species, for melanoma patients a high number of diagnostic ions, present with high frequency and with quite high relative abundance, are present, in particular, in serum samples and, to a lesser extent, also in plasma. Since plasma samples are obtained more easily in comparison to sera, it is possible to suggest that plasma can also be used for these studies.

[1]  E. Urso,et al.  Search of plasma markers for colorectal cancer by matrix-assisted laser desorption/ionization mass spectrometry. , 2005, Journal of mass spectrometry : JMS.

[2]  M. Lise,et al.  Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers. , 2003, Rapid communications in mass spectrometry : RCM.

[3]  S. Ottó,et al.  Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. , 2003, European journal of cancer.

[4]  N. Kitchen,et al.  Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: A pilot study , 2002, Critical care medicine.

[5]  R. Sherwood,et al.  Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma , 2002, The British journal of dermatology.

[6]  R. Molina,et al.  S-100 Protein Serum Levels in Patients with Benign and Malignant Diseases: False-Positive Results Related to Liver and Renal Function , 2002, Tumor Biology.

[7]  D. Menon,et al.  Discordant temporal patterns of S100 β and cleaved tau protein elevation after head injury: a pilot study , 2002, British journal of neurosurgery.

[8]  G. Friedman,et al.  Increased serum S100β protein concentrations following severe head injury in humans: a biochemical marker of brain death? , 2001, Neuroreport.

[9]  L. Hansson,et al.  Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Hauschild,et al.  Quantification of melanoma-associated molecules in plasma/serum of melanoma patients. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[11]  M. Lise,et al.  Protein profiles in sera of patients with malignant cutaneous melanoma. , 2000, Rapid communications in mass spectrometry : RCM.

[12]  U. Hipler,et al.  Serum protein S100β in patients with malignant melanoma detected by an immunoluminometric assay , 2000, Journal of Cancer Research and Clinical Oncology.

[13]  K. Haglid,et al.  A New Specific Method for Measuring S-100B in Serum , 2000, The International journal of biological markers.

[14]  K. Nicolaides,et al.  Maternal serum S100 protein in normal and Down syndrome pregnancies , 1999, Prenatal diagnosis.

[15]  C. Heizmann,et al.  Supratentorial Pilocytic Astrocytomas, Astrocytomas, Anaplastic Astrocytomas and Glioblastomas are Characterized by a Differential Expression of S100 Proteins , 1999, Brain pathology.

[16]  R. Sherwood,et al.  Serum S‐100 protein: a potentially useful prognostic marker in cutaneous melanoma , 1997 .

[17]  R. Sherwood,et al.  Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. , 1997, The British journal of dermatology.

[18]  H. Joller-jemelka,et al.  Serum S100--a marker for disease monitoring in metastatic melanoma. , 1997, Dermatology.

[19]  B. Stoffel‐Wagner,et al.  Clinical significance of serum S100 in metastatic malignant melanoma. , 1995, European journal of cancer.

[20]  A. Burlingame,et al.  Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Alexander Marks,et al.  S100 protein and down syndrome , 1990, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  D. Hilt,et al.  The S100 protein family. , 1988, Trends in biochemical sciences.

[23]  C. Laterre,et al.  Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. , 1988, Clinical chemistry.

[24]  Kanefusa Kato,et al.  Differential distribution of immunoreactive S100-alpha and S100-beta proteins in normal nonnervous human tissues. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[25]  T. Isobe,et al.  A rapid separation of S100 subunits by high performance liquid chromatography: the subunit compositions of S100 proteins. , 1983, Biochemistry international.

[26]  V. Hearing,et al.  Serum and Urine Protein Differences in Patients With Malignant Melanoma , 1980 .

[27]  J. D. Morrison,et al.  Computer methods in analytical mass spectrometry. Identification of an unknown compound in a catalog , 1968 .

[28]  J. Fahey,et al.  Serum-Protein Changes in Malignant Disease. II. The Chronic Leukemias, Hodgkin's Disease, and Malignant Melanoma , 1960 .

[29]  J. Fahey,et al.  Serum protein changes in malignant diseases. I. The acute leukemias. , 1960, Blood.